scholarly journals Vulvar Cancer with Cutaneous and Breast Metastases

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Nawaraj Adhikari ◽  
Adarsh Vennepureddy ◽  
Sara Parylo ◽  
Anupma Agarwal ◽  
Meekoo Dhar

Vulvar cancer accounts for about 5% of cancer of female genitalia. It may initially present as benign symptoms resulting in potential delay in diagnosis. Few cases of distant metastases to skin or breast have been reported. We present the case of a 76-year-old female with possible delay in diagnosis of her squamous cell carcinoma of vulva. After 4 months of the diagnosis, she presented with concurrent cutaneous and breast metastases.

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hirofumi Tomioka ◽  
Yuko Yamagata ◽  
Yu Oikawa ◽  
Toshimitsu Ohsako ◽  
Takuma Kugimoto ◽  
...  

AbstractThe control of distant metastasis in oral squamous cell carcinoma is an important determinant of improved prognosis. The study aimed to identify risk factors for distant metastasis in patients with locoregionally controlled oral carcinoma. We identified 982 patients with oral squamous cell carcinoma treated at our hospital between January 2008 and December 2017. After excluding patients with distant metastasis at initial treatment, patients with metastasis to the oral cavity, those receiving palliative treatment, and those lacking follow-up data, 941 patients were selected. Finally, among these 941 patients, 887 with locoregionally controlled oral squamous cell carcinoma were included in the study. Among the 887 patients, 36 had confirmed distant metastasis (4.1%), and the lung was the most common site (31/36 patients, 86.1%). Multivariate analysis showed that the incidence of primary intraosseous carcinoma of the mandible, cervical lymph node metastasis at levels IV and V, and the presence of pathological extranodal extension were significant risk factors for distant metastasis. When treating patients with oral squamous cell carcinoma who are positive for the aforementioned risk factors, the possibility of developing distant metastases must be accounted for, and aggressive treatment should be planned accordingly.


2013 ◽  
Vol 42 (1) ◽  
pp. 53 ◽  
Author(s):  
Brittany R Barber ◽  
Vincent L Biron ◽  
Alexander C Klimowicz ◽  
Lakshmi Puttagunta ◽  
David WJ Côté ◽  
...  

2005 ◽  
Vol 97 (3) ◽  
pp. 904-907 ◽  
Author(s):  
Lukas A. Hefler ◽  
Gerhard Sliutz ◽  
Sepp Leodolter ◽  
Paul Speiser ◽  
Elmar Joura ◽  
...  

2018 ◽  
Vol 31 (06) ◽  
pp. 353-360 ◽  
Author(s):  
Cindy Kin

AbstractSquamous cell carcinomas of the anal canal and the anal margin are rare malignancies that are increasing in incidence. Patients with these tumors often experience delayed treatment due to delay in diagnosis or misdiagnosis of the condition. Distinguishing between anal canal and anal margin tumors has implications for staging and treatment. Chemoradiation therapy is the mainstay of treatment for anal canal squamous cell, with abdominoperineal resection reserved for salvage treatment in cases of persistent or recurrent disease. Early anal margin squamous cell carcinoma can be treated with wide local excision, but more advanced tumors require a combination of chemoradiation therapy and surgical excision.


1989 ◽  
Vol 75 (6) ◽  
pp. 597-599 ◽  
Author(s):  
Marco Benasso ◽  
Alejandro Ferro ◽  
Almalina Bacigalupo ◽  
Salvatore Toma ◽  
Silvio Vitriolo ◽  
...  

The present paper reports a retrospective analysis of 16 patients with distant metastases from squamous cell carcinoma of the head and neck observed in our Institute in the last 10 years. Nine patients out of 16 underwent chemotherapy (7 patients), chemotherapy and radiotherapy (1 patient), or an alternating chemo-radiotherapy regimen (1 patient). The remaining 7 patients were not considered for a palliative treatment because of a poor performance status. Two complete responses, 2 partial responses, 2 stable diseases and 3 progressions were observed, with an overall response rate of 44 %. Chemotherapy, when administrable, showed a temporary effectiveness, at least in patients with lung metastases. The combination of cisplatin and 5-fluorouracil seems to maintain the efficacy already shown in patients with locally relapsed disease.


Sign in / Sign up

Export Citation Format

Share Document